Paper36769824
miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL.
Zhang J and 7 others. J Clin Med, 2023. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL. Papers, record 36769824. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36769824
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2021-SO-105 | 345 TALENT PROJECT OF SHENGJING HOSPITAL | PubMed | ||
| 2020-MS-177 | NATURAL SCIENCE FOUNDATION OF LIAONING PROVINCE, CHINA | PubMed |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29156006 | DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29156006 | PubMed |
| 2 | 35922756 | MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy. | Mol Med | 2022 | https://conductscience.org/library/papers/35922756 | PubMed |
| 3 | 36176756 | An overview of resistance to chemotherapy in osteosarcoma and future perspectives. | Cancer Drug Resist | 2022 | https://conductscience.org/library/papers/36176756 | PubMed |
| 4 | 32192573 | Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32192573 | PubMed |
| 5 | 32576626 | The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32576626 | PubMed |
| 6 | 22475227 | Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. | BMC Cancer | 2012 | https://conductscience.org/library/papers/22475227 | PubMed |
| 7 | 34207685 | Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34207685 | PubMed |
| 8 | 19160414 | Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. | J Cell Physiol | 2009 | https://conductscience.org/library/papers/19160414 | PubMed |
| 9 | 31528224 | Long non-coding RNA TUG1 mediates 5-fluorouracil resistance by acting as a ceRNA of miR-197-3p in colorectal cancer. | J Cancer | 2019 | https://conductscience.org/library/papers/31528224 | PubMed |
| 10 | 31572452 | lncRNA OSTN-AS1 May Represent a Novel Immune-Related Prognostic Marker for Triple-Negative Breast Cancer Based on Integrated Analysis of a ceRNA Network. | Front Genet | 2019 | https://conductscience.org/library/papers/31572452 | PubMed |
| 11 | 35647294 | Silencing circular RNA-friend leukemia virus integration 1 restrained malignancy of CC cells and oxaliplatin resistance by disturbing dyskeratosis congenita 1. | Open Life Sci | 2022 | https://conductscience.org/library/papers/35647294 | PubMed |
| 12 | 33922820 | Role of MicroRNAs in Human Osteosarcoma: Future Perspectives. | Biomedicines | 2021 | https://conductscience.org/library/papers/33922820 | PubMed |
| 13 | 29118673 | MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. | Cancer Cell Int | 2017 | https://conductscience.org/library/papers/29118673 | PubMed |
| 14 | 35074616 | MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner. | Leuk Res | 2022 | https://conductscience.org/library/papers/35074616 | PubMed |
| 15 | 33272173 | MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma. | Curr Mol Med | 2021 | https://conductscience.org/library/papers/33272173 | PubMed |
| 16 | 33536026 | Hsa_circ_0025202 suppresses cell tumorigenesis and tamoxifen resistance via miR-197-3p/HIPK3 axis in breast cancer. | World J Surg Oncol | 2021 | https://conductscience.org/library/papers/33536026 | PubMed |
| 17 | 32767242 | The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32767242 | PubMed |
| 18 | 14679136 | Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. | Ann Oncol | 2004 | https://conductscience.org/library/papers/14679136 | PubMed |
| 19 | 31632022 | Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy. | Int J Nanomedicine | 2019 | https://conductscience.org/library/papers/31632022 | PubMed |
| 20 | 34818481 | New Horizons in the Treatment of Osteosarcoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34818481 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42444836 | Proliferation of pleural mesothelioma cells is enhanced by the microRNA-197-3p activity. | Front Oncol | 2026 | https://conductscience.org/library/papers/42444836 | PubMed |
| 42022572 | Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42022572 | PubMed |
| 41035670 | The paradoxical role of stem cells in osteosarcoma: from pathogenesis to therapeutic breakthroughs. | Front Oncol | 2025 | https://conductscience.org/library/papers/41035670 | PubMed |
| 41009512 | Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009512 | PubMed |
| 40504347 | Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40504347 | PubMed |
| 40429954 | The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40429954 | PubMed |
| 38686047 | Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1α/HK2 and SLC7A11 pathway. | Oncol Res | 2024 | https://conductscience.org/library/papers/38686047 | PubMed |
| 37937197 | Identification of the methotrexate resistance-related diagnostic markers in osteosarcoma via adaptive total variation netNMF and multi-omics datasets. | Front Genet | 2023 | https://conductscience.org/library/papers/37937197 | PubMed |
| 37740818 | Circ_103809 Aggravates the Malignant Phenotype of Pancreatic Cancer Through Modulating miR-197-3p/TSPAN3 Axis. | Mol Biotechnol | 2024 | https://conductscience.org/library/papers/37740818 | PubMed |
| 37523046 | SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling. | J Neurooncol | 2023 | https://conductscience.org/library/papers/37523046 | PubMed |
Genes33
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36769824
GET https://conductscience.org/api/papers/v1/36769824/references?page=2